Frølund L, Madsen F, Svendsen U G, Weeke B
Respiration. 1986;50 Suppl 2:270-3. doi: 10.1159/000195143.
Twenty-one stable asthmatic patients were randomly allocated to be treated with either Duovent (ipratropium bromide 40 micrograms and fenoterol 100 micrograms) and Berodual (ipratropium bromide 20 micrograms and fenoterol 50 micrograms) in a cross-over double-blind design over a 12-week period, each treatment period lasting for 6 weeks. During the study, patients used the test medicine 2 puffs 4 times daily. At the day of inclusion, 6 and 12 weeks after start, a dose-response curve was obtained after inhalation of the test medicine used during the previous 6-week period. Asthma symptoms were recorded in a diary card and morning and evening peak flow was measured. Berodual and Duovent showed a significant bronchodilating effect, the effect of Duovent comparatively more pronounced, but the absolute lung function values after Berodual equalized the effect of Duovent. No difference between peak flow values measured in the morning and evening could be demonstrated. We conclude that no preference between either Duovent or Berodual could be established in the treatment of asthma.
21名病情稳定的哮喘患者被随机分配，采用交叉双盲设计，在12周内分别接受多索茶碱（异丙托溴铵40微克和非诺特罗100微克）和贝罗都（异丙托溴铵20微克和非诺特罗50微克）治疗，每个治疗期持续6周。在研究期间，患者每天使用测试药物4次，每次2喷。在纳入研究当天、开始治疗后6周和12周，吸入前6周使用的测试药物后获得剂量反应曲线。哮喘症状记录在日记卡上，并测量早晚的峰值流速。贝罗都和多索茶碱均显示出显著的支气管扩张作用，多索茶碱的作用相对更明显，但贝罗都治疗后的绝对肺功能值与多索茶碱的作用相当。早晚测量的峰值流速值之间未显示出差异。我们得出结论，在哮喘治疗中，多索茶碱和贝罗都之间无法确定偏好。
